Please Wait.....
Report
India Diabetes Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)
Market Report I 2025-06-01 I 75 Pages I Mordor Intelligence
India Diabetes Devices Market Analysis
The India diabetes devices market is valued at USD 2.25 billion in 2025 and is forecast to reach USD 2.52 billion by 2030, expanding at a 2.28% CAGR. Structural shifts shaping the India diabetes devices market include the government's Production Linked Incentive (PLI) scheme that has cleared 19 green-field projects covering 44 formerly imported device categories. Adoption of digital health is rising, with more than 400,000 patients using platforms such as Apollo Sugar for remote monitoring. Continuous glucose monitoring (CGM) reimbursement pilots under public schemes, expanding pharmacy-led programs, and employer-funded digital benefits are broadening access, even as high GST on consumables and patchy cold-chain logistics restrain growth. Multinational and domestic firms are racing to localize manufacturing, integrate connected solutions, and secure distribution footprints that reach tier-2/3 cities.
India Diabetes Devices Market Trends and Insights
Rising Prevalence of Obesity Among Youth Increasing Earlier Onset Diabetes
Government surveys show 24% of women and 23% of men ages 15-49 are overweight or obese, accelerating diabetes onset and shifting device demand toward technology-centric monitoring. Younger patients adopt CGMs more readily than finger-stick glucometers, driving rapid uptake in urban metros. Digital platforms report high engagement from users under 35, and clinicians increasingly recommend continuous monitoring earlier in the disease course. Growing urban lifestyles that foster metabolic syndrome are widening the addressable market for advanced devices and stimulating manufacturers to launch youth-oriented product lines.
Expanding Public Reimbursement for CGM Sensors
Pilot programs under the Central Government Health Scheme and Employee State Insurance Corporation now reimburse CGM sensors for Type-1 and insulin-dependent Type-2 patients. Private insurers such as ICICI Lombard have released diabetes plans bundling device coverage, yet reimbursement ceilings remain below retail prices, limiting mass adoption. Over time, broader coverage is expected to spur volume growth and encourage manufacturers to localize production to meet price points aligned with public budgets.
High GST Slab (12%) on Testing Consumables
The 12% GST on glucometer strips inflates recurring costs for frequent testers, impeding adherence among low-income patients. Advocates urge re-classification as essential devices to achieve tax exemption comparable to life-saving drugs. Price pressure favors bundled strip-subscription models from online platforms that spread payments over time, yet overall uptake in semi-urban zones remains constrained
Other drivers and restraints analyzed in the detailed report include:
Rising Prevalence & Earlier Onset of Type-2 Diabetes / Pharmacy-led Diabetes Management Programs / Government PLI Scheme for Local Device Production / Patchy Cold-chain for Insulin Cartridges in Tier-3 Cities /
For complete list of drivers and restraints, kindly check the Table Of Contents.
Segment Analysis
Monitoring devices held 58.12% of 2024 revenue, underscoring their foundational role for India's 77 million diabetics. The India diabetes devices market size for monitoring products is projected to expand at 2.1% CAGR as commoditization drives price competition. Continuous glucose monitoring outpaces legacy glucometers inside the monitoring portfolio, aided by sensor accuracy gains and mobile app integration. Meanwhile, management devices-comprising insulin pumps, smart pens, and delivery accessories-register a 3.54% CAGR. Hospitals implementing closed-loop systems and employer health plans covering pumps propel segment growth. The India diabetes devices market share of management devices may therefore edge upward as affordability improves and bundled reimbursement widens.
Price disparities remain stark: Abbott's discontinued INR 2,000 Libre Pro formerly lowered barriers, whereas current alternatives exceed INR 5,000. Domestic entrants exploring reusable transmitters and low-cost sensors aim to restore affordability. Studies from tertiary centers reveal HbA1c drops of 1.1 percentage points among CGM users versus finger-stick cohorts. Evidence supports clinician advocacy for continuous monitoring, expanding long-run penetration beyond affluent urban niches.
Type-2 patients account for 92.14% revenue and represent the fastest-growing pool owing to lifestyle risk factors. The India diabetes devices market size linked to Type-2 users is forecast to rise steadily at 3.89% CAGR through 2030. Early-onset diagnosis shifts purchasing behavior-young professionals demand connected devices that sync with fitness apps while retirees stay with basic glucometers. Digital twin interventions delivered over smartphone platforms help 89% of Type-2 users achieve HbA1c below 7% in controlled studies.
Type-1 patients, though fewer, remain heavy per-capita consumers of pumps, CGMs, and patch pens. Continuous innovation in closed-loop algorithms first targets this cohort, with cost reductions over time filtering into Type-2 indications. Gestational and other specific diabetes categories form a high-acuity niche addressed by hospital-based CGM rental models during pregnancy.
The Indian Diabetes Device Market is Segmented by Device Type (Monitoring Devices and Management Devices), Patient Type (Type-1 Diabetes, Type-2 Diabetes, and Gestational & Other Specific Types), End User (Home-Care Settings, and Hospitals & Specialty Clinics), Sales Channel (Pharmacy Retail and Pharmacy Retail). The Report Offers the Value (in USD) and Volume (in Units) for the Above Segments.
List of Companies Covered in this Report:
Abbott Laboratories / Medtronic / Roche / Becton Dickinson (BD) / Novo Nordisk / Sanofi / Eli Lilly and Company / Dexcom / Insulet / Tandem Diabetes Care / Ypsomed / LifeScan (J&J) / Ascensia / Terumo / Nipro / HTL-Strefa / AgVa Healthcare / Beckton Dickinson / Senseonics / Sugarmate /
Additional Benefits:
The market estimate (ME) sheet in Excel format /
3 months of analyst support /
1 Introduction
1.1 Study Assumptions & Market Definition
1.2 Scope of the Study
2 Research Methodology
3 Executive Summary
4 Market Landscape
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Prevalence of Obesity Among Youth Increasing Earlier Onset Diabetes
4.2.2 Expanding public reimbursement for CGM sensors
4.2.3 Rising prevalence & earlier onset of Type-2 diabetes
4.2.4 Pharmacy-led diabetes management programs
4.2.5 Government PLI scheme for local device production
4.2.6 Employer-funded health-tech benefit platforms
4.3 Market Restraints
4.3.1 High GST slab (12%) on testing consumables
4.3.2 Patchy cold-chain for insulin cartridges in tier-3 cities
4.3.3 Low CGM prescription awareness among primary physicians
4.3.4 Data-privacy concerns around connected pumps
4.4 Value-/Supply-Chain Analysis
4.5 Regulatory Landscape
4.6 Technological Outlook
4.7 Porter's Five Forces Analysis
4.7.1 Threat of New Entrants
4.7.2 Bargaining Power of Suppliers
4.7.3 Bargaining Power of Buyers
4.7.4 Threat of Substitutes
4.7.5 Competitive Rivalry
5 Market Size & Growth Forecasts
5.1 By Device Type (Value)
5.1.1 Monitoring Devices
5.1.1.1 Self-Monitoring Blood Glucose (SMBG)
5.1.1.1.1 Glucometers
5.1.1.1.2 Test Strips
5.1.1.1.3 Lancets
5.1.1.2 Continuous Glucose Monitoring (CGM)
5.1.1.2.1 Sensors
5.1.1.2.2 Durables (Transmitters/Receivers)
5.1.2 Management Devices
5.1.2.1 Insulin Pumps
5.1.2.1.1 Pump Device
5.1.2.1.2 Pump Reservoir
5.1.2.1.3 Infusion Set
5.1.2.2 Insulin Syringes
5.1.2.3 Insulin Cartridges
5.1.2.4 Disposable Pens
5.2 By Patient Type
5.2.1 Type-1 Diabetes
5.2.2 Type-2 Diabetes
5.2.3 Gestational & Other Specific Types
5.3 By End User
5.3.1 Hospitals & Specialty Clinics
5.3.2 Home-Care Settings
5.4 By Sales Channel
5.4.1 Pharmacy Retail
5.4.2 E-commerce & D-to-C
6 Market Indicators
6.1 Type-1 Diabetes Population
6.2 Type-2 Diabetes Population
7 Competitive Landscape
7.1 Market Concentration
7.2 Market Share Analysis
7.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
7.3.1 Abbott
7.3.2 Medtronic
7.3.3 Roche
7.3.4 Becton Dickinson (BD)
7.3.5 Novo Nordisk
7.3.6 Sanofi
7.3.7 Eli Lilly
7.3.8 Dexcom
7.3.9 Insulet
7.3.10 Tandem Diabetes Care
7.3.11 Ypsomed
7.3.12 LifeScan (J&J)
7.3.13 Ascensia Diabetes Care
7.3.14 Terumo
7.3.15 Nipro
7.3.16 HTL-Strefa
7.3.17 AgVa Healthcare
7.3.18 BeatO
7.3.19 Senseonics
7.3.20 Sugarmate
8 Market Opportunities & Future Outlook
8.1 White-space & Unmet-Need Assessment
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security